Romiplostim Market Report 2024 (Global Edition)

Global Romiplostim Market Report 2024 Market Size Split by Type (250 μg/0.5 mL, 500 μg/1 mL), by Application (Adults, Pediatric Patients), by End-User (Hospitals, Clinics, Homecare), by Distribution...

Romiplostim Market Report Description

We have various report editions of Romiplostim Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Romiplostim Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Romiplostim Industry News

In November 2012, Amgen announced that Nplate(TM) (romiplostim) is given marketing authorization in the European Union (EU) based on a positive judgement from the European Committee for Medicinal Products for Human Use (CHMP). For adults with splenectomized chronic immune thrombocytopenia purpura (ITP) who are not responding to alternative therapies, such as corticosteroids or immunoglobulins, the CHMP suggests Nplate. When surgery is not recommended, nplate may be used as a second line of treatment for adult non-splenectomized patients.

In October 2022, according to European Medicines Agenc, Nplate was proven to be beneficial for treating long-standing ITP in two major adult studies and a third study including children. In every study, Nplate was contrasted with a placebo, or fake treatment. The primary indicator of therapy efficacy for the patients, who had a 24-week course of treatment, was an increase in platelet count exceeding a threshold of 50 million platelets per millilitre of blood for at least six of the final eight weeks of treatment.

(Source: https://www.ema.europa.eu/en/medicines/human/EPAR/nplate)

Top Companies Market Share in Romiplostim Industry: (In no particular order of Rank)

• AMGEN
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

In terms of revenue, the North America Romiplostim Market share was 40% of the total market

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Throughout the projection period, the rising incidence of thrombocytopenia, a disorder marked by a low platelet count, is anticipated to fuel the need for romiplostim. Every week, a subcutaneous injection of romiplostim is administered. Each person will require a different dosage of romiplostim. The duration of the course of treatment will also differ for each patient. The substantial research being done on treating the specified ailment and the global increase in healthcare spending, both of which would increase the market's size and allow pharmaceutical companies to further enter it. 

The Asia Pacific region is witnessing increasing research and development of romiplostim. Businesses and researchers are attempting to evaluate obstacles and look for chances that may impact the supremacy of romiplostim. Novel techniques to treat or enhance the disease status are the main focus of the medicines now under development. Romiplostim is facing competition from other approved medications for the condition, and the market will be greatly impacted in the near future by the introduction of late-stage developing therapies.

The current report Scope analyzes Romiplostim Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Romiplostim

According to Cognitive Market Research, the global romiplostim market size was estimated at USD XX Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031. In North America, rising environmental awareness, incentives from the government, and technological developments anticipated to drive the market growth during the forecast period. Opportunities exist in the Romiplostim market for a number of stakeholders, including adults and paediatric patients. Romiplostim Injection market investment, R&D efforts, and policy development can all be expedited by working together between the public and commercial sectors. Furthermore, the increasing demand from consumers offers opportunities for market growth. 

• According to Cognitive Market Research, the US had a major share in the romiplostim market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Increasing technological developments in manufacturing of romiplostim is driving the market growth.
• The Canada romiplostim market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period due to the rising demand for romiplostim in paediatric patients.
• The Mexico romiplostim market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD XX million in 2024.

Europe Romiplostim Market

According to Cognitive Market Research, with a market value of USD XX million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD XX million. Increasing infrastructure developments is one of the factor anticipated to fuel the market expansion during the forecast period. Furthermore, industry cooperation, consumer trends and preferences, government laws and regulations, and technological breakthroughs are projected to propel the market growth.

• The United Kingdom romiplostim market had a market share of USD 209.27 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. The increasing government initiatives and policies to propel the market growth. 

• The France romiplostim market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the Germany romiplostim market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period due to the growing number of romiplostim suppliers in the Germany.
• The Italy romiplostim market is projected to witness growth at a CAGR of 3.9% during the forecast period with a market size of USD XX million in 2024.
• The Russia romiplostim market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD XX million in 2024.
• The Spain romiplostim market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD XX million in 2024.
• The Luxembourg romiplostim market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD XX million in 2024.
• The Portugal romiplostim market is projected to witness growth at a CAGR of 4.3% during the forecast period with a market size of USD XX million in 2024.
• The Greece romiplostim market is projected to witness growth at a CAGR of 4.8% during the forecast period with a market size of USD XX million in 2024.
• Rest of Europe romiplostim market is projected to witness growth at a CAGR of 3.2% during the forecast period with a market size of USD XX million in 2024.

Asia Pacific Romiplostim

According to Cognitive Market Research, the global romiplostim market size was estimated at USD XX Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031 due to the change in lifestyle and rising urbanization in the region. Moreover, growing product launches by major market players anticipated to drive the market growth during the forecast period.

• According to Cognitive Market Research, the China romiplostim market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period due to the technological advancements manufacturing of romiplostim. 
• The Japan romiplostim market is projected to witness growth at a CAGR of 6.5% during the forecast period with a market size of USD XX million in 2024.
• The India romiplostim market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. Increasing demand of romiplostim.
• The South Korea romiplostim market is projected to witness growth at a CAGR of 7.1% during the forecast period with a market size of USD XX million in 2024.
• The Australia romiplostim market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD XX million in 2024.
• The South East Asia romiplostim market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD XX million in 2024.
• The Rest of Asia Pacific romiplostim market is projected to witness growth at a CAGR of 7.8% during the forecast period with a market size of USD XX million in 2024.

South America Romiplostim

According to Cognitive Market Research, the global romiplostim market size was estimated at USD XX Million out of which Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. Increasing use of romiplostim in different therapies is anticipated to drive the market growth. Adults with immune thrombocytopenia (ITP, idiopathic thrombocytopenic purpura; a chronic illness that may cause easy bruising or bleeding due to an abnormally low number of platelets in the blood) can reduce their risk of bleeding by using romiplostim injection to increase the number of platelets (cells that help the blood clot). Additionally, in children who have had ITP for at least six months and are at least one year old, romiplostim injection is used to boost platelet counts in an effort to reduce the risk of bleeding. 

• According to Cognitive Market Research, the Brazil romiplostim market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Rising use of romiplostine in bone marrow to increase the platelet count.

• The Argentina romiplostim market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period due to the surge in the number of companies launching romiplostim drug. 
• The Colombia romiplostim market is projected to witness growth at a CAGR of 5.2% during the forecast period with a market size of USD XX million in 2024.
• The Peru romiplostim market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD XX million in 2024.
• The Chile romiplostim market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD XX million in 2024.
• The Rest of Latin America romiplostim market is projected to witness growth at a CAGR of 4.5% during the forecast period with a market size of USD XX million in 2024.

Middle East and Africa Romiplostim

According to Cognitive Market Research, the global romiplostim market size was estimated at USD XX Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031. Increasing use of romiplostim in the treatment of chronic immune thrombocytopenia is driving the market growth. Adults with immune thrombocytopenia (ITP, idiopathic thrombocytopenic purpura; a chronic illness that may cause easy bruising or bleeding due to an abnormally low number of platelets in the blood) can reduce their risk of bleeding by using romiplostim injection to increase the number of platelets (cells that help the blood clot). Additionally, in children who have had ITP for at least six months and are at least one year old, romiplostim injection is used to boost platelet counts in an effort to reduce the risk of bleeding.

• According to Cognitive Market Research, the GCC Countries romiplostim market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period due to the romiplostim injection is use to raise platelet counts sufficiently to reduce the risk of bleeding. The Egypt romiplostim market is projected to witness growth at a CAGR of 6.0% during the forecast period with a market size of USD XX million in 2024.
• The South Africa romiplostim market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD XX million in 2024. Romiplostim belongs to a group of drugs known as agonists of the thrombopoietin receptor. It functions by inducing an increase in platelet production in the bone marrow cells.
• The Turkey romiplostim market is projected to witness growth at a CAGR of 5.2% during the forecast period with a market size of USD XX million in 2024.
• The Nigeria romiplostim market is projected to witness growth at a CAGR of 4.8% during the forecast period with a market size of USD XX million in 2024.
• The Rest of MEA romiplostim market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD XX million in 2024.

Romiplostim Market Analysis

Romiplostim Market Type Segment Analysis

According to Cognitive Market Research, 250 μg/0.5 Ml held the major market share over the forecast period Romiplostim dosing can be individualised with upto 10 mcg/kg1 as the maximum weekly dose. The starting dosage for is determined on the patient's actual weight. The subcutaneous injections of romiplostim once a week with adjusting the dose in accordance with the platelet count response are important factor. If achieving and maintaining a platelet count of at least 50 x 109/L is required to lower the risk of bleeding, use the lowest dose. When determining the dosage, the patient's actual body weight at the start of therapy should always be used.

500 μg/1 mL is the fastest-growing category over the forecast period. romiplostim provides a weekly subcutaneous injection in-office. There's no need to keep in mind to take a medication each day. There is no liver monitoring and no history of pharmacological interactions with statins, antacids, or antihypertensive drugs. No known dietary limitations (such as when administered with or without meals), therefore bread, milk, cereal, ice cream, cheese, and tofu are all acceptable.

• 250 μg/0.5 mL
• 500 μg/1 mL

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Romiplostim Industry. Request a Free Sample PDF!

Romiplostim Market Application Segment Analysis

According to Cognitive Market Research, adult hold a prominent market share. In order to lower the risk of bleeding in people with immune thrombocytopenia, romiplostim injection is used to increase the amount of platelets, which are cells that aid in blood clotting. Adults with either persistent or recently diagnosed immune thrombocytopenia are used with romiplostim. For adults, rimiplostim is advised as a second or third line of treatment for primary immune thrombocytopenia (ITP). 

A Paediatric patient is the fastest-growing category over the forecast period. Children with persistent or recently diagnosed primary immune thrombocytopenia are treated with romiplostim. The illness of heterogeneous origin, immune thrombocytopenia (ITP) is typified by reduced platelet counts and an increased propensity to haemorrhage.  Most youngsters with ITP have a transient illness and don't require medical intervention. Short doses of steroids are advised for children with newly diagnosed ITP who exhibit increased bleeding symptoms. Because of their efficacy and safety characteristics, romiplostim are advised for children who do not respond to first-line treatment or who develop a steroid dependency.

• Adults
• Pediatric Patients

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Romiplostim End-User Segment Analysis

According to Cognitive Market Research, hospitals hold a prominent market share. There are several exams that fall in between non-surgical therapies and surgical procedures. Hospital treatment involves one or more healthcare providers providing, managing, or coordinating medical care and related services. A health care provider's management or coordination of treatment with a third party is provided in the hospitals which are driving the market growth during the forecast period. Consultation about a patient between medical professionals is one of the main focusing points for patients visiting to the hospital which is anticipated to propel the market growth.

Clinics are the fastest-growing category over the forecast period. Clinics are medical facilities that treat patients without requiring an overnight stay, with an emphasis on outpatient care. In addition to basic health care, they usually offer preventative treatments such screenings, immunisations, and exams which is projected to fuel the market expansion in the coming years. 

• Hospitals
• Clinics
• Homecare

Romiplostim Distribution Channel Segment Analysis

According to Cognitive Market Research, hospital pharmacies hold a prominent market share comprise establishments including medical facilities, clinics for outpatient treatment, drug-dependency treatment centres, poison control centres, and residential care facilities. Giving patients and other healthcare providers advice on how to use medications safely and effectively is another crucial area. In order to maximise patient outcomes, hospital pharmacies offer medicine selection, prescription writing, procurement, delivery, administration, and review services. When using any medication, it is crucial to make sure that the proper patient, dose, administration method, time, drug, information, and documentation are followed. 

Retail pharmacies are the fastest-growing category over the forecast period. The increasing prevalence of chronic illnesses necessitates extended pharmaceutical regimens, which in turn fuels the demand for retail pharmacies in the market. It is anticipated that a rise in the diagnosis of chronic illnesses will fuel rapid expansion in retail pharmacies. In addition to providing individualised and highly individualised care to patients with chronic medical illnesses, pharmacies are able to meet the needs of people with both relatively basic and difficult medical conditions. 

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion